Patient volumes picked up as the lockdowns gradually eased to varying extent since June 2020. In addition, the magnitude of Covid-19 related-services provided by the group also increased as the pandemic continues. The group was in active collaboration with the public healthcare sector of the countries it operates in since late January 2020 to treat Covid-19 patients, as well as to provide Covid-19 screening, laboratory testing and vaccination services.
IHH Healthcare Berhad announced that its 1HFY2021 ended June saw earnings of RM858.9 million ($277.1 million), reversing out of a RM440.4 million loss in 1HFY2020.
This came on the back of a 34% increase in revenue to RM8.2 billion, compared to RM6.1 billion a year ago. The group explains that 1HFY2020 was a low base due to major lockdowns in various markets that it operates in, including Singapore, Malaysia India and Turkey as a result of the Covid-19 pandemic. During this period, patients postponed non-urgent and non-essential treatment and visits to hospitals and healthcare facilities.
